Aurobindo Pharma Limited has received the approval from the US Food and Drug Administration (USFDA) to manufacture and market Sildenafil injection.

According to the company, the drug is bio-equivalent and therapeutically equivalent to the reference listed drug product Revatio (Sildenafil) Injection of Pfizer.

In a statement issued by Aurobindo Pharma, this is the ninth Abbreviated New Drug Application (ANDA) represented by 7 product classes to be approved out of Unit 5 formulations facility of the company in Hyderabad. The product will be marketed and sold by the company’s wholly owned subsidiary AuroMedics Pharma LLC.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.